Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (651-660 of 842) with videos related to

Pageof 85
Sort By:
Cardiovascular Research|January 2, 2021
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart diseaseAlexander P Benz, Jeff S Healey, Ashley Chin, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
European Journal of Heart Failure|March 29, 2019
Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk scoreChristopher O'Connor, Mona Fiuzat, Hillary Mulder, et al.
JACC. Heart Failure|March 7, 2026
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCarolyn S P Lam, Biykem Bozkurt, David Z I Cherney, et al.
QJM : Monthly Journal of the Association of Physicians|May 17, 2015
Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysisC Berry, K K Poppe, G D Gamble, et al.
Circulation. Heart Failure|January 22, 2024
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID TrialJosephine Harrington, Robert J Mentz, Frank W Rockhold, et al.
JACC. Heart Failure|January 7, 2019
NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEFMelissa A Daubert, Kirkwood Adams, Eric Yow, et al.
JACC. Heart Failure|October 11, 2020
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction StudyJustin A Ezekowitz, Christopher M O'Connor, Richard W Troughton, et al.
Circulation. Heart Failure|October 8, 2025
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA SubstudyPalak Shah, Yinggan Zheng, Burkert Pieske, et al.
Kidney International|March 6, 2026
Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCarolyn S P Lam, Biykem Bozkurt, David Z I Cherney, et al.
Pageof 85

Showing results (651-660 of 842) with videos related to

Sort By:
Pageof 85
Cardiovascular Research|January 2, 2021
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart diseaseAlexander P Benz, Jeff S Healey, Ashley Chin, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
European Journal of Heart Failure|March 29, 2019
Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk scoreChristopher O'Connor, Mona Fiuzat, Hillary Mulder, et al.
JACC. Heart Failure|March 7, 2026
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCarolyn S P Lam, Biykem Bozkurt, David Z I Cherney, et al.
QJM : Monthly Journal of the Association of Physicians|May 17, 2015
Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysisC Berry, K K Poppe, G D Gamble, et al.
Circulation. Heart Failure|January 22, 2024
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID TrialJosephine Harrington, Robert J Mentz, Frank W Rockhold, et al.
JACC. Heart Failure|January 7, 2019
NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEFMelissa A Daubert, Kirkwood Adams, Eric Yow, et al.
JACC. Heart Failure|October 11, 2020
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction StudyJustin A Ezekowitz, Christopher M O'Connor, Richard W Troughton, et al.
Circulation. Heart Failure|October 8, 2025
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA SubstudyPalak Shah, Yinggan Zheng, Burkert Pieske, et al.
Kidney International|March 6, 2026
Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCarolyn S P Lam, Biykem Bozkurt, David Z I Cherney, et al.
Pageof 85